在接受维护透析的患者中,萨库比特里尔-瓦尔萨坦的作用
Ying Ding1, Li Wan1, Zhou-Cang Zhang1
1Department of Nephrology, Peking University International Hospital, Beijing, PR. China.
Renal failure
|June 19, 2023
概括
萨库比特里尔-瓦尔萨坦 (SV) 在透析患者中显示出心脏保护作用,显著降低尿素水平,改善左心室喷射率,特别是在腹腔透析患者中. 在治疗期间监测血清.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 关于在接受维持透析的患者中使用血管激素受体-尼普利辛抑制剂 (ARNI) 萨库比特里尔-瓦尔萨坦 (SV) 的数据有限.
- 透析的末期病患者往往具有高心血管风险和有限的治疗选择.
研究的目的:
- 为了调查sacubitril-valsartan (SV) 在接受维护透析 (腹透析[PD]或血液透析[HD]) 的末期病 (ESRD) 患者的作用和安全性.
主要方法:
- 一项回顾性研究,将51名接受SV治疗的ESRD患者与51名接受透析但没有SV的年龄和性别匹配的对照进行了比较.
- 在基线和随访期间 (中位数为349天) 记录了临床,生化和心声学参数.
- 评估了包括高胆血症,低血压和血管在内的安全结果.
主要成果:
- 治疗SV显著降低了B型性尿素 (BNP) 和N-终端亲B型性尿素 (NT-proBNP) 的水平.
- 在SV组中观察到左心室喷射分数 (LVEF) 的改善率更高,特别是在PD患者中.
- 治疗SV的结果显示,水分过多的趋势有所减少,高胆固醇血症或不良事件的发生率没有显著增加.
结论:
- 萨库比特利-瓦尔萨坦 (SV) 可能为透析的ESRD患者提供心脏保护性益处,特别是腹腔透析 (PD) 患者.
- 在这种人群中,建议在SV治疗期间密切监测血清水平.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
469
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
469
01:22Heart Failure Drugs: Diuretics
426
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
426
01:30Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
01:27Dialysis
390
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
390
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
789
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
789
01:11Renal Failure: Dose Adjustments
127
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
127